The organizer of this upcoming Zoom presentation by Dr. Jeanne Loring graciously invites HU-Cure Parkinson's UK forum members to listen in on this timely update revealing what is on the horizon for 'induced pluripotent stem cell' therapies. All are welcome.
"Dear Friends,
"We look forward to seeing you on Thursday, February 17th at 2:00 pm, for our monthly Zoom get-together. We are delighted to have Dr. Jeanne Loring as our February guest speaker.
"Dr. Loring is professor emeritus and founding director of the Center for Regenerative Medicine at the Scripps Research Institute, and co-founder of Aspen Neuroscience. Her research focuses on pluripotent stem cells and stem cell treatment for Parkinson’s Disease. She was our guest speaker in February 2020, and will provide us with an update on her research. (scripps.edu/faculty/loring/)
*The Zoom instructions are:
Time: Feb 17, 2022 02:00 PM Pacific Time (US and Canada)
Has anything happened at Aspen? They raised $70million in April 2020. The most recent press release I can see on the site is October 2020. If anything significant has happened, like registering and recruiting for a clinical trial, why have Aspen been so coy about it?
1) Notes FDA authority has been received for the pretrial ipsc production for a phase 1a trial. Basically growing a stock of cells to be implanted in the patients they were grown from. This was due to start "end of this year beginning of next" so maybe Jeanne Loring was able to announce that this phase has started. This is undoubtedly a really positive thing, tempered only by my memory of a Jeanne Loring video from before my diagnosis in 2018 which gave the unmistakable impression that the PD hopefuls in the video would be the trial subjects "any day now"
2) they are looking for partners so the $70 million they raised 2 years ago was not enough and, regardless of the FDA approval situation they need, and in October didn't have, big bucks to move onto clinical trials. Maybe Loring was able to say how much they need and how much they have raised
3) It sought to promote the autologous route generally, and the Aspen route particularly over the non-autologous route using the recent monkey study which showed autologous transplants in monkeys were more effective than non-autologous WITHOUT IMMUNOSUPPRESSANTS. This was a bit muddled since all it really does is reinforce the bleedin obvious advantage of autologous, namely that immunosuppressants are not required. But it implied that it showed autologous had a better outcome regardless of immunosuppressants. Which is a bit cheeky when you have just shown some of the amazing clinical success of human featal transplants as "proof of concept" for stem cell therapy. It also disregards the fact that the only human ispc transplant I am aware of (George Lopez) has not been a great success, and they quoted the success of a study where human ispc were transplanted into rats - which is hardly autologous (not even same species). Maybe Zhittya aren't so bad after all.
Maybe someone who was able to attend the webinar could update us (or maybe Jeanne Loring focused on saving Rhino's)
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Dr. Simon Stott's recording is now available- PD research round up 2021 & looking ahead to 2022
Parkinson's and Mitohormesis - presentation by Dr. Matthew CL Phillips
